Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InflaRx N.V. (IFRX : NSDQ)

• Company Description    InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. Number of Employees: 74

• Price / Volume Information    Yesterday's Closing Price: $0.90 Daily Weekly Monthly 20 Day Moving Average: 265,377 shares Shares Outstanding: 67.13 (millions) Market Capitalization: $60.10 (millions) Beta: 1.29 52 Week High: $2.82 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.90% 7.71% 12 Week -15.55% -28.96% Year To Date -63.76% -66.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL WINZERLAER STR. 2 - JENA,2M 07745 DEU ph: 49-36-4150-8180 fax: 49-36-4150-8181 ir@inflarx.com http://www.inflarx.de

• General Corporate Information    Officers Niels Riedemann - Chief Executive Officer Nicolas Fulpius - Chairman Thomas Taapken - Chief Financial Officer Renfeng Guo - Director Mark Kubler - Director Peer Information InflaRx N.V. (CORR.) InflaRx N.V. (RSPI) InflaRx N.V. (CGXP) InflaRx N.V. (BGEN) InflaRx N.V. (GTBP) InflaRx N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N44821101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 67.13 Most Recent Split Date: (:1) Beta: 1.29 Market Capitalization: $60.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: 324.85 EPS Growth vs. Year Ago Period: 26.32% vs. Previous Quarter: -55.56% Sales Growth vs. Year Ago Period: 106.06% vs. Previous Quarter: 1,842.86% ROE 06/30/25 - - 03/31/25 - -64.17 12/31/24 - -60.70 ROA 06/30/25 - - 03/31/25 - -53.39 12/31/24 - -51.79 Current Ratio 06/30/25 - - 03/31/25 - 5.28 12/31/24 - 5.06 Quick Ratio 06/30/25 - - 03/31/25 - 4.86 12/31/24 - 4.57 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -33,646.85 12/31/24 - -27,782.01 Book Value 06/30/25 - - 03/31/25 - 1.11 12/31/24 - 1.13 Inventory Turnover 06/30/25 - - 03/31/25 - 0.38 12/31/24 - 0.35 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©